We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RENX:NASDAQRenX Enterprises Corp. Analysis

Data as of 2026-07-06 - not real-time

$2.07

Latest Price

8/10Risk

Risk Level: High

Executive Summary

RenX Enterprises Corp. is trading well below its long‑term average price and sits beneath both its short‑term and mid‑term moving averages, indicating a bearish price structure. The relative strength index is perched in the upper half of its range, suggesting modest upward momentum, while the MACD shows a bullish histogram, hinting at a possible short‑term reversal. However, trading volume has been on a downtrend, the stock exhibits an exceptionally high beta and volatility, and the price is approaching a recently identified support level. On the fundamentals side, revenue growth has been spectacular, yet margins are deeply negative, cash flow is negative, and leverage is extreme despite a recent equity conversion that trimmed debt. The combination of technical weakness, financial distress, and a sector that is sensitive to economic cycles creates a precarious outlook.
Given the current market sentiment of extreme greed, the stock’s price‑to‑book multiple is high relative to its book value, and there is no dividend to cushion downside. Investors should treat RenX as a high‑risk speculative play, with any upside hinging on a successful operational turnaround and continued debt reduction.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 4/10

Key Factors

  • Bearish price alignment with moving averages
  • Bullish MACD histogram indicating possible short‑term bounce
  • Decreasing volume and high volatility

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Continued revenue growth but persistent negative margins
  • Recent debt‑to‑equity conversion improving balance sheet
  • Sector exposure to real‑estate cycles

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Extreme leverage and negative cash flow
  • High beta and volatility exposing investors to market swings
  • Lack of sustainable earnings or dividend support

Key Metrics & Analysis

Financial Health

Revenue Growth21683.80%
Profit Margin-190.01%
ROE-3006.93%
ROA-33.25%
Debt/Equity2139.62
P/B Ratio4.2
Op. Cash Flow$-8495325
Free Cash Flow$-3041766
Industry P/E32.6

Technical Analysis

TrendBearish
RSI61.9
Support$1.60
Resistance$2.12
MA 20$1.80
MA 50$1.95
MA 200$8.58
MACDBullish
VolumeDecreasing
Fear & Greed Index93.63

Valuation

GradeOvervalued
TypeGrowth

Risk Assessment

Beta2.46
Volatility66.56%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.